In a recent study (91), VEGFC was shown to inhibit the activation of NLRP3 inflammatory vesicles by promoting autophagy to ameliorate sensitized hypertension and nephritis, which may be a potential therapeutic target for HTN. The gene discussed is NLRP3; the disease is hypertensive disorder.